Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

8.37
+0.07000.84%
Post-market: 8.450.0795+0.95%17:44 EDT
Volume:2.07M
Turnover:17.47M
Market Cap:486.62M
PE:-3.39
High:8.67
Open:8.32
Low:8.26
Close:8.30
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:0.69
T/O Rate:4.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:1.98
PE(LYR):-3.70

Loading ...

Health ROUNDS-Experimental Drug Helps Advanced Cancer Patients Avoid Bladder Removal Surgery

Reuters
·
Jul 31

Capricor Therapeutics downgraded to Hold from Buy at JonesResearch

TIPRANKS
·
Jul 31

Health Rounds: Experimental Cell Therapy Slows Heart Failure Progression in Duchenne Muscular Dystrophy

Reuters
·
Jul 31

U.S. Stocks on the MOVE-Mastercard, Starbucks, Meta

Reuters
·
Jul 30

Capricor Therapeutics Hit 52-Week Low on Negative FDA Panel Vote

Dow Jones
·
Jul 30

Capricor: FDA committee voted evidence did not support Deramiocel effectiveness

TIPRANKS
·
Jul 30

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

THOMSON REUTERS
·
Jul 30

Capricor Therapeutics - Targets August 22, 2026 Pdufa Date for Deramiocel FDA Decision

THOMSON REUTERS
·
Jul 30

Capricor Therapeutics Inc : Maxim Group Cuts to Hold from Buy

THOMSON REUTERS
·
Jul 30

Capricor Therapeutics Inc. : Oppenheimer Cuts to Perform from Outperform

THOMSON REUTERS
·
Jul 30

Street View: Capricor in 'precarious Position' as Approval in Doubt

Reuters
·
Jul 30

HC Wainwright Downgrades Capricor Therapeutics to Neutral From Buy

MT Newswires Live
·
Jul 30

Capricor Therapeutics Cut to Neutral from Buy by HC Wainwright & Co.

Dow Jones
·
Jul 30

Capricor Therapeutics resumes trading, shares sink 55% to $2.99

TIPRANKS
·
Jul 30

Capricor Therapeutics Shares Down 52% Premarket After FDA Panel Votes Against Co's Duchenne Heart Disease Therapy

THOMSON REUTERS
·
Jul 30

U.S. Research ROUNDUP-Equinix, Meta, S&P Global

Reuters
·
Jul 30

Capricor Therapeutics Inc : Piper Sandler Cuts to Neutral from Overweight; Cuts Target Price to $2 from $58

THOMSON REUTERS
·
Jul 30

FDA panel votes 9-3 against Capricor’s deramiocel

TIPRANKS
·
Jul 30

Capricor downgraded to Neutral from Overweight at Cantor Fitzgerald

TIPRANKS
·
Jul 30

FDA Advisers Vote Against Capricor's Duchenne Heart Disease Therapy

Reuters
·
Jul 30